Intended Use

LGI-Flag™ is a computational software tool that is intended to identify individuals at risk for lower GI disorders that warrant further evaluation. It is based on complete blood count (CBC) patterns mainly related to erythrocyte features, measured and derived from peripheral venous blood specimens. LGI-Flag™ is indicated for use in individuals of the general population, between 50 and 75 years of age, who are not under active GI surveillance.

LGI-Flag™ 3.0 is recommended for use by healthcare systems and their affiliates (such as care providers and population health managers) within their Information Technology (IT) systems. LGI-Flag™ is an adjunct to established clinical guidelines and a referral for further evaluation should be based on the clinical judgment of the care provider.

Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s of millions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities